Related Experiment Video
Updated: May 31, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting SRC in mucinous ovarian carcinoma
Koji Matsuo1, Masato Nishimura, Justin N Bottsford-Miller
1Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, University of Texas, 77230, USA.
Summary
Mucinous ovarian cancer patients have worse survival and resistance to chemotherapy. Targeting Src kinase with dasatinib and oxaliplatin shows promise for treating this aggressive ovarian cancer subtype.
Area of Science:
- Gynecologic Oncology
- Cancer Biology
- Translational Research
Background:
- Mucinous ovarian carcinomas (MOCs) present a distinct clinical profile compared to other ovarian cancer subtypes.
- Understanding the stage-specific significance and therapeutic vulnerabilities of MOCs is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the stage-specific clinical significance of MOCs in a large patient cohort.
- To investigate the functional role of Src kinase in preclinical models of MOC.
Main Methods:
- Survival analyses were performed on 1,302 ovarian cancer patients, including 122 with MOC.
- The effects of Src kinase inhibition were assessed using dasatinib in an orthotopic MOC model (RMUG-S-ip2).
Main Results:
- Advanced-stage MOC patients exhibited significantly poorer survival rates compared to serous histology.
- Src kinase activity was highest in RMUG-S-ip2 cells, and dasatinib inhibited oxaliplatin-induced Src phosphorylation.
- Targeting Src with dasatinib demonstrated significant antitumor effects in the MOC model, enhanced by combination therapy with oxaliplatin.
Conclusions:
- Poor survival in MOC is linked to resistance to cytotoxic therapies.
- Combining dasatinib with oxaliplatin represents a potential therapeutic strategy for MOC.
